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Dear Editor,
Psoriasis is a chronic immune-mediated hyperproliferative
inflammatory skin disease of unknown etiology character-
ized by the appearance of sore patches of thick, red skin
with silvery scales. It affects about up to 3 % of the world
population and it is equally prevalent in both genders,
although results from a recent study have shown that on
average, men have more severe forms of the disease.
Psoriasis treatment often requires a varied team of
clinicians with a range of expertise due to the fact that high
prevalence, chronicity, disfiguration, disability, and asso-
ciated comorbidity characterize the disease. The deep
understanding of the role of immune function in psoriasis
permits the management of this complex disease, which
dramatically affects patients far beyond the skin.
Hence, psoriasis is associated with impairment in health
related quality of life, and, recently, it has emerged as a
systemic disease, which affects not only cutaneous and
articular sites, but it can also result in metabolic impairments
and adverse cardiovascular outcomes [1]. Cytokines and
growth factors released by activated T cells have been shown
to display a prominent role in keratinocyte hyperprolifera-
tion; however, we focused our attention on dermal
fibroblasts, which are also directly involved in the developing
psoriatic lesions accelerating keratinocyte proliferation [1].
Emerging research suggests that reactive oxygen species
(ROS) play a central role in the pathogenesis of psoriasis.
Indeed, a number of studies reveal an altered blood redox
status in psoriatic patients as shown by significantly
increased levels of oxidative stress markers and decreased
activity of the main antioxidant enzymes [2]. SIRT1, a
mammalian ortholog of Silent information regulator 2
(Sir2) family, is significantly upregulated in response to
oxidative stress [3]. Sirtuins are a family of NAD?-de-
pendent protein deacetylases that are evolutionally con-
served from yeast to human. SIRT1, the most extensively
studied member of the sirtuin family, targets a number of
substrates—histones, transcription factors, DNA repair
proteins, autophagy factors, and others—to modulate
metabolism, stress responses, and many other cellular
processes [3]. We have previously demonstrated that
SIRT1 activation regulates mitogen-activated protein
kinases (MAPK) pathway and down-regulates pro-apop-
totic molecules, decreasing oxidative stress and reducing
apoptotic cell death in keratinocytes from vitiligo skin.
In the literature, there is neither evidence for SIRT1
expression and activity in lesional psoriatic fibroblasts, nor
for its possible involvement in oxidative stress-related
pathways. Here, for the first time, we investigated SIRT1
expression and activity in a fibroblast primary culture from
lesional psoriatic skin, and we hypothesize its involvement
in oxidative-mediated alterations.
The study was approved by the Local Ethics Committee,
and carried out according to the Helsinki Declaration.
Analyses were carried out in eight patients (four females
and four males) affected by moderate psoriasis
(PASI = 12.5 ± 0.5) with a mean age of 40.1 ± 8.7 years
and with a mean duration of disease of 15.8 years (from 8
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to 25 years). The demographic and clinical information for
each patient are summarized in Table 1. Ten non-stressed
healthy controls (five females and five males), matched for
age and body mass index, were also enrolled in the study.
No subjects involved in the study followed any systemic
therapy before the study, or had a history of any disease,
e.g., diabetes mellitus and atherosclerosis, which might
affect the redox status.
SIRT1 expression was assessed by confocal microscopy
analysis (a) and quantified by western blot (b). As shown in
Fig. 1a, SIRT1 expression is markedly reduced in fibrob-
lasts from psoriatic patients compared to healthy subject; in
particular, western blot analysis confirms the reduction of
SIRT1 expression in psoriatic fibroblasts compared to
controls (-43 ± 5 % vs Controls).
SIRT1 activity was assessed using SIRT1 Direct Fluo-
rescent Screening Assay Kit (Cayman, Ann Arbor, MI,
USA) as previously described [4]. Compared with fibrob-
lasts from healthy subjects, psoriatic cells exhibit a marked
decrease (325.8 ± 58.42 vs 724.3 ± 123.9, p\ 0.0001) in
SIRT1 activity.
This is the first evidence for a reduced SIRT1
expression and activity in lesional psoriatic fibroblasts,
suggesting the involvement of SIRT1 in the pathogenesis
of psoriasis. Many aspects remain to be elucidated;
however, therapeutic strategies based on SIRT1 activa-
tors might also be taken into consideration to control the
metabolic and cardiovascular derangement of the disease
[5].
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Table 1 Demographic and
clinical data of patients involved
in the study
Patients Age BMI Duration of disease (years) PASI
M1 33 25 8 13
M2 41 24 12 13
M3 29 25 10 12
M4 52 23 21 12
F1 51 21 25 13
F2 45 23 20 13
F3 38 26 18 12
F4 32 24 12 12
Mean ± SD 40.1 ± 8.7 23.9 ± 1.6 15.8 ± 6.1 12.5 ± 0.5
Fig. 1 Confocal microscope (a), western blot (b) analyses of SIRT1
expression and SIRT1 activity (c) in a fibroblast primary culture from
lesional psoriatic skin and healthy controls
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